Ascorbic Acid Significantly Decreases Creatine Kinase Plasma Levels in an Animal Model of Statin/Fibrate-Induced Myopathy

Copyright © 2021 Mohsen Zabihi et al..

BACKGROUND: Myopathy is one of the side effects of lipid-lowering drugs, especially statins and particularly when combined with a fibrate. To diagnose myopathy and determine its severity, the plasma levels of three enzymes, creatine kinase (CK), aldolase, and lactate dehydrogenase (LDH), are routinely measured. Physical exercise can aggravate the statin-associated muscular disease. The question is whether antioxidants like ascorbic acid (Vit. C) can prevent such myopathy.

METHODS: In this experiment, a combination of atorvastatin (ATV, 80 mg/kg/day) and gemfibrozil (GMF, 1000 mg/kg/day) orally for 10 days as well as exercise as forced swimming on days 8, 9, and 10 were used to induce myopathy. Ascorbic acid (50 mg/kg/day, orally) was added to ATV/GMF plus exercise regimen throughout the 10 days in the treatment group. Mean blood levels of CK, aldolase, and LDH were measured in addition to swimming tolerance times.

RESULTS: There was a significantly higher swimming tolerance time (P < 0.05) and lower CK levels (P < 0.01) in rats receiving ATV/GMF/Vit. C plus exercise compared with rats not taking Vit. C. LDH and aldolase did not decrease significantly.

CONCLUSION: The results of this study showed that Vit. C can be effective in preventing myopathy caused by fat-lowering drugs.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:2021

Enthalten in:

Advances in pharmacological and pharmaceutical sciences - 2021(2021) vom: 21., Seite 5539595

Sprache:

Englisch

Beteiligte Personen:

Zabihi, Mohsen [VerfasserIn]
Askarian, Fatemeh [VerfasserIn]
Hekmatimoghaddam, Seyedhossein [VerfasserIn]
Rashidi Nooshabadi, Mohammadreza [VerfasserIn]
Zabihi, Mohammad Sajjad [VerfasserIn]
Mousavinasab, Seyed Ruhollah [VerfasserIn]

Links:

Volltext

Themen:

Journal Article

Anmerkungen:

Date Revised 30.04.2022

published: Electronic-eCollection

Citation Status PubMed-not-MEDLINE

doi:

10.1155/2021/5539595

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM335408877